Advertisement
UK markets close in 2 hours 49 minutes

  • FTSE 100

    8,099.30
    +58.92 (+0.73%)
     

  • FTSE 250

    19,738.56
    +19.19 (+0.10%)
     

  • AIM

    755.70
    +1.01 (+0.13%)
     

  • GBP/EUR

    1.1666
    +0.0021 (+0.18%)
     

  • GBP/USD

    1.2475
    +0.0012 (+0.10%)
     

  • Bitcoin GBP

    51,223.91
    -2,177.01 (-4.08%)
     

  • CMC Crypto 200

    1,361.60
    -20.98 (-1.52%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    83.28
    +0.47 (+0.57%)
     

  • GOLD FUTURES

    2,340.90
    +2.50 (+0.11%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    18,000.33
    -88.37 (-0.49%)
     

  • CAC 40

    8,025.62
    -66.24 (-0.82%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Bavarian Nordic to Host First Half 2021 Results Conference Call and Webcast

Bavarian Nordic A/S
·2-min read

COPENHAGEN, Denmark – August 18, 2021 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2021 first half results on Wednesday, August 25, 2021.

The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at https://bit.ly/3xzOiQo.

To join the Q&A session dial one of the following numbers and state the participant code 8569159: Denmark: +45 32 72 80 42, UK: +44 (0) 844 571 8892, USA: +1 631-510-7495.

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine based on an in-licensed capsid virus-like particle technology. The vaccine candidate, ABNCoV2, is currently being investigated in clinical trials. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Tel: +45 61 77 47 43
U.S.: Graham Morrell, Paddock Circle Advisors (US), Tel: +1 781 686 9600